Earnings Call · Q4 FY2025·2026-03-19

Q4 25EPS +23.43%·Rev n/aQ3 25EPS 0.00%·Rev n/aQ2 25EPS -14.29%·Rev n/aQ1 25EPS 0.00%·Rev n/a⚠ consensus missing

Taysha Gene Therapies, Inc. TSHA

Hayleigh Collins — Investor Relations

Sean Nolan — Chief Executive Officer

Sukumar Nagendran — President and Head of R&D

Kamran Alam — CHIEF FINANCIAL OFFICER

+2.5%1d on move date+2.7% vs SPY3d+2.0%5d+2.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TSHA calls or request research access.

More TSHA calls Browse calls Request research access